{
    "clinical_study": {
        "@rank": "142782", 
        "arm_group": [
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator"
            }, 
            {
                "arm_group_label": "Avanafil 100 mg", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Avanafil 200 mg", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "The objectives of this study are to examine the therapeutic effects of two doses of avanafil\n      after dosing in men with erectile dysfunction"
        }, 
        "brief_title": "Research Evaluating a PDE5 Inhibitor for Erectile Dysfunction", 
        "completion_date": {
            "#text": "April 2013", 
            "@type": "Actual"
        }, 
        "condition": "Erectile Dysfunction", 
        "condition_browse": {
            "mesh_term": "Erectile Dysfunction"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Males \u2265 18 years of age;\n\n          -  Minimum 6 months of erectile dysfunction;\n\n          -  In a monogamous, heterosexual relationship for at least 3 months;\n\n          -  Agree to make at least 4 attempts at intercourse per month;\n\n          -  Provide written informed consent;\n\n          -  Agree not to use any other ED treatments for erectile dysfunction;\n\n          -  Willing and able to comply with all study requirements.\n\n        Exclusion Criteria:\n\n          -  Allergy or hypersensitivity to PDE5 inhibitors;\n\n          -  History of dose-limiting AEs with a PDE5 inhibitor or discontinued use of a PDE5\n             inhibitor;\n\n          -  Concomitant use of one or more of the following medications:\n\n               -  Other prescription or OTC drugs known to interfere with metabolism by the CYP\n                  3A4 enzyme;\n\n               -  Dose of an alpha blocker that has not been stable for at least 14 days;\n\n               -  Any nitrate;\n\n          -  ED as a consequence of advanced neurologic disease, spinal cord injury,or radical\n             prostatectomy;\n\n          -  Myocardial infarction, stroke, life-threatening arrhythmia or coronary\n             revascularization within the past 6 months;\n\n          -  Unstable angina, angina with sexual intercourse, or congestive heart failure > NYHA\n             Class II;\n\n          -  Poorly controlled type 1 or type 2 diabetes;\n\n          -  Evidence of prostate cancer or previous radical prostatectomy;\n\n          -  Untreated hypogonadism or total testosterone levels outside normal reference range;\n\n          -  Abnormal laboratory value(s) judged to be clinically significant by the investigator;\n\n          -  Positive urine drug screen;\n\n          -  History of retinitis pigmentosa, nonarteritic anterior ischemic optic neuropathy or\n             glaucoma;\n\n          -  Previous participation in any other study with avanafil;\n\n          -  Use of any other investigational medication or device for any indication within 30\n             days prior to enrollment or at any time during this study;\n\n          -  Evidence of any clinically significant medical, psychiatric, social or other\n             condition by history, physical examination or laboratory studies that, in the opinion\n             of the investigator, would contraindicate the administration of study medications,\n             affect compliance, interfere with study evaluations, limit study participation,\n             contraindicate sexual activity or confound the interpretation of study results."
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "440", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "September 25, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01698684", 
            "org_study_id": "TA-501"
        }, 
        "intervention": [
            {
                "arm_group_label": "Placebo", 
                "description": "One dose 15 minutes before attempting intercourse", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Avanafil 100 mg", 
                "description": "One dose 15 minutes before attempting intercourse", 
                "intervention_name": "Avanafil 100 mg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Avanafil 200 mg", 
                "description": "One dose 15 minutes before attempting intercourse", 
                "intervention_name": "Avanafil 200 mg", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Phosphodiesterase 5 Inhibitors"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "ED", 
        "lastchanged_date": "January 13, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Jupiter", 
                        "country": "United States", 
                        "state": "Florida"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Raleigh", 
                        "country": "United States", 
                        "state": "North Carolina"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Wilmington", 
                        "country": "United States", 
                        "state": "North Carolina"
                    }
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Randomized, Double-Blind, Placebo-Controlled Evaluation of Avanafil for On-Demand Treatment of Men With Erectile Dysfunction", 
        "overall_official": {
            "affiliation": "VIVUS, Inc.", 
            "last_name": "Chuck Bowden, M.D.", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "April 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Change in percentage of sexual attempts in which subjects are able to maintain an erection of sufficient duration to have successful intercourse", 
            "safety_issue": "No", 
            "time_frame": "Week 0 (Baseline), Week 8 (End of Study)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01698684"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "VIVUS, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "VIVUS, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}